Q1 Earnings Forecast for PepGen Issued By Leerink Partnrs

PepGen Inc. (NASDAQ:PEPG - Free Report) - Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for PepGen in a research note issued on Monday, February 24th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.75) per share for the quarter, up from their prior estimate of ($0.76). The consensus estimate for PepGen's current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for PepGen's Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.21) EPS and FY2026 earnings at ($2.93) EPS.

A number of other equities research analysts have also weighed in on the company. Bank of America lowered PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research note on Monday, December 16th. Wedbush decreased their target price on PepGen from $19.00 to $12.00 and set an "outperform" rating for the company in a report on Friday, November 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of PepGen in a report on Monday, February 24th.

PepGen Trading Up 29.6 %

Shares of PEPG stock traded up $0.72 during trading hours on Wednesday, reaching $3.15. 8,938,895 shares of the company's stock were exchanged, compared to its average volume of 4,157,341. PepGen has a 1 year low of $1.16 and a 1 year high of $19.30. The stock has a market cap of $102.68 million, a PE ratio of -1.06 and a beta of 1.53. The stock's fifty day moving average price is $2.37 and its two-hundred day moving average price is $5.69.

Remove Ads

PepGen (NASDAQ:PEPG - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.13.

Institutional Investors Weigh In On PepGen

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC lifted its holdings in shares of PepGen by 29.1% during the third quarter. Jane Street Group LLC now owns 27,748 shares of the company's stock worth $237,000 after purchasing an additional 6,254 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in PepGen in the fourth quarter valued at approximately $26,000. Northern Trust Corp lifted its holdings in PepGen by 5.4% in the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company's stock valued at $595,000 after acquiring an additional 7,984 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in PepGen in the third quarter valued at approximately $95,000. Finally, Dimensional Fund Advisors LP lifted its holdings in PepGen by 26.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,102 shares of the company's stock valued at $216,000 after acquiring an additional 11,870 shares during the period. Institutional investors and hedge funds own 58.01% of the company's stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.